BlueWind Medical Raises $64 Million to Fund Innovative Technology for Overactive Bladder (OAB) Treatment
BlueWind Medical Raises $64 Million to Fund Innovative Technology for Overactive Bladder (OAB) Treatment. The RENOVA iStim™ implantable tibial neuromodulation device is being studied as a minimally invasive, patient-centric solution for the treatment of OAB.
Park City, Utah, and Herzliya, Israel—May 9, 2022 – BlueWind Medical, Ltd., the developer of the innovative RENOVA iStim implantable tibial neuromodulation device under investigation for the treatment of urgency incontinence alone or in combination with urinary urgency and/or urinary frequency, today announced the closing of a $64 million Series B funding round.
This round of financing was led by ConvaTec, a global medical products and technologies company focused on therapies for the management of chronic conditions, including continence care. “Proceeds from the financing will be used to support the ramp-up in our commercial footprint in anticipation of potential FDA marketing clearance for BlueWind Medical’s RENOVA iStim implantable neuromodulation device,” said Dan Lemaitre, Chairman & CEO of BlueWind Medical.
According to the American Urological Association, OAB is a chronic, debilitating condition affecting over 34 million Americans and can lead to urgency urinary incontinence (UUI), the involuntary leakage of urine associated with a sudden compelling desire to void. People diagnosed with UUI have an irreversible condition that substantially impacts their physical and mental health and is significantly associated with depression, social isolation, obesity, and death.1 2 3
BlueWind Medical completed patient enrollment of the OASIS pivotal clinical study in November 2021 at 23 centers in the United States, United Kingdom, The Netherlands, and Belgium. Interim safety data were recently announced at the SUFU (Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction) Winter Meeting showing no device or procedure-related serious adverse events. BlueWind Medical will submit an application for U.S. Food & Drug Administration (FDA) marketing clearance in the United States later in 2022 based on the OASIS pivotal study.
The RENOVA iStim device utilizes neuromodulation to target the nerves that control the bladder. RENOVA iStim is implanted near the ankle in a single short outpatient procedure of approximately 30 minutes utilizing local anesthesia. “At ConvaTec, we focus on solutions that improve the lives of those enduring chronic conditions like incontinence. We believe BlueWind Medical’s vision for less invasive care with greater customer control will resonate with end-users and providers alike,” said Seth Segel, President & COO, Global Continence Care and Home Services Group of ConvaTec Group Plc. “The BlueWind team appreciates that ConvaTec and others share our vision in the potential for RENOVA iStim to transform the care of OAB,” concluded Lemaitre.
About BlueWind Medical Ltd: BlueWind Medical was founded in Israel in 2010 and has an extensive patent portfolio, including 15 patent families, 35 filings, and 24 issued patents. BlueWind Medical obtained CE Mark for RENOVA iStim in the treatment of overactive bladder in 2016. The OASIS study is being conducted under an Investigational Device Exemption (IDE) from the FDA. RENOVA iStim is not approved for use in the U.S. For additional information, please visit BlueWindMedical.com.
About ConvaTec: The group is a global medical products and technologies company focused on solutions for the management of chronic conditions. It is listed in the FTSE 250 and holds leading positions in advanced wound care, ostomy care, continence and critical care, and infusion care. ConvaTec has more than 10,000 colleagues and sells its products and services in over 90 countries. The company’s vision is to pioneer trusted medical solutions to improve the lives of those it touches.
ConvaTec’s products offer a range of clinical and economic benefits, including infection prevention, protection of at-risk skin, improved patient outcomes, and reduced total cost of care. The group’s revenues in 2021 exceeded $2 billion. For further information about ConvaTec, please visit http://www.convatecgroup.com.
For Investor Relations, please contact Chuck Cargile, Chief Financial Officer, BlueWind Medical, at (435) 565-1822. For Public Relations, please contact Sandra Muhlfeld, Vice President of Marketing, BlueWind Medical, at (435) 255-3061.
1. Coyne KS, Kvasz M, Ireland AM, Milsom I, Kopp ZS, Chapple CR. Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. Eur Urol. 2012;61(1):88–95.
2. Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013;67(10):1015–1033.
3. Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000 Jul;6(11 Suppl):S580-90. PMID: 11183901